1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
TRANS GENIC GROUP INC.

TRANS GENIC GROUP INC.

TTSE:2342
207.00
JPY
-6.00
(-2.82%)
4.26BMarket Cap
Nov 12Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
119.4
141.8
164.99
160.6
243.11
512.54
636.05
636.02
734.08
678.57
778.7
781.88
791.1
- -
Basic EPS, GAAP
-8.39
1.29
1.05
5.63
1.41
11.95
-25.38
31.45
109.52
-24.32
0.24
-65.51
-4.64
- -
Free Cash Flow per Basic Share
-18.44
3.93
7.82
7.16
9.79
-10.21
-15.99
61.99
73.38
-103.08
-39.17
-4.89
-2.56
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
3.04
5.99
4.99
2.98
0.01
- -
Book Value per Share
199.12
199.7
215.49
221.08
266.33
281.55
254.3
283.08
388.45
356.99
355.2
285.99
287.04
- -
Tangible Book Value per Share
181.86
185.33
203.48
211.96
233.51
252.88
223.18
252.33
365.98
323.32
323.08
252.73
256.66
- -
Basic Weighted Avg Shares
14
14
14
14
15
17
17
17
17
17
17
17
17
17
Sales/Revenue/Turnover
1,618
1,959
2,290
2,303
3,601
8,675
11,047
11,046
12,577
11,430
13,083
13,005
13,174
- -
Operating Margin (%)
-5.26
1.21
2.2
6.68
1.68
3.11
1.57
8.09
14.61
-0.22
0.68
-2
1.05
- -
Depreciation Expense
85
94
104
112
144
190
230
251
228
184
150
242
156
- -
Net Income, GAAP
-114
18
15
81
21
202
-441
546
1,876
-410
4
-1,090
-77
- -
Effective Tax Rate (%)
- -
- -
23.06
1.51
- -
0.32
- -
21.97
32.8
- -
90.74
- -
- -
- -
Profit Margin (%)
-7.03
0.91
0.64
3.5
0.58
2.33
-3.99
4.95
14.92
-3.58
0.03
-8.38
-0.59
- -
Working Capital
1,586
1,510
1,225
1,209
2,137
1,771
2,329
3,647
5,050
4,818
4,115
3,427
2,860
- -
LT Debt
93
26
35
5
553
312
1,062
1,632
1,076
1,738
1,308
1,356
953
- -
Total Equity
2,765
2,777
3,070
3,173
4,342
4,887
4,417
5,037
6,637
6,123
5,998
4,856
4,840
- -
Return on Invested Capital (%)
- -
- -
1.29
4.76
- -
5.04
- -
10.41
15.54
- -
0.1
- -
- -
- -
Return on Capital (%)
- -
- -
0.55
2.59
- -
3.95
- -
8.65
24.64
- -
0.1
- -
- -
- -
Return on Common Equity (%)
-4.52
0.65
0.5
2.59
0.56
4.38
-9.47
11.71
32.78
-6.53
0.07
-20.45
-1.62
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
1,705
1,136
- -
LT Borrowings
1,155
953
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
3,597
4,263
3,497

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
6,789
6,709
- -
Cash, Cash Equivalents & STI
2,212
2,135
- -
Accounts Receivable, Net
996
1,115
- -
Inventories
2,738
2,473
- -
Total Current Liabilities
3,533
3,848
- -
Payables & Accruals
- -
- -
- -
ST Debt
1,705
1,136
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.98%
0.52%
-0.34%
Free Cash Flow
-102.91%
-83.75%
-47.7%
Net Income, GAAP
-2,614.16%
-5,369.29%
-92.91%
Sales/Revenue/Turnover
- -
3.98%
1.3%
Total Cash Common Dividend
- -
- -
-99.64%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
13,005
2026
- -
- -
- -
- -
13,174
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-65.51
2026
- -
- -
- -
- -
-4.64
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2.98
2026
- -
- -
- -
- -
0.01
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kenji Fukunaga
Full Time Employees
227
Sector
Health technology
Industry
Biotechnology
Address
2-3-36 Tenjin Fukuoka FK Japan 810-0001
IPO Date
Dec 10, 2002
Website
transgenic-group.co.jp
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
TransGenic Group Inc. (2342.T) develops, distributes, licenses, and manufactures genetically modified animals, antibodies, and related research reagents primarily for drug discovery support in Japan. The company operates through Drug Discovery Support and Investment business segments, offering glycan synthesis and analysis services; non-clinical studies using small animals such as mice and rats, and large animals such as primates for pharmaceuticals, foods, cosmetics, and chemical substances; safety tests and pharmacological efficacy studies; bioequivalence testing support including clinical trials, pharmacokinetic measurements, and clinical trial reports; hospital support services; contract production of genetically modified mice, knockout mice, genome-edited mice, humanized mice, high-affinity antibodies, protein hybrids, and expressing cells; basic research services encompassing gene function analysis, disease model creation, and gene expression analysis; clinical trials for functional foods and specific health foods; and advice on M&A, business revitalization, and succession, along with sales of mouse-related products, model mice, and frozen embryos. TransGenic Group Inc. primarily serves pharmaceutical companies, research institutions, and food developers in the biotechnology and life sciences industries, with operations centered in Japan. Founded in 1998 and headquartered in Fukuoka City, Japan, the company changed its name from Trans Genic Inc. to TransGenic Group Inc. in October 2024 to reflect its expanded group structure and strategic focus on hybrid drug discovery support and investment activities.